Cargando…
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
Worldwide, colorectal cancer (CRC) is the third most frequently diagnosed cancer in men and the second in women. Metastatic disease develops in more than half of the patients and carries a poor prognosis. Over the past three decades, significant advances have been made in the treatment of metastatic...
Autores principales: | Dietvorst, Maria H. P., Eskens, Ferry A. L. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873022/ https://www.ncbi.nlm.nih.gov/pubmed/24392302 http://dx.doi.org/10.1007/s13554-013-0009-6 |
Ejemplares similares
-
Aflibercept in the Treatment of Metastatic Colorectal Cancer
por: Wang, Tzu-Fei, et al.
Publicado: (2012) -
Ziv-aflibercept in metastatic colorectal cancer
por: Patel, Anuj, et al.
Publicado: (2013) -
Ziv-Aflibercept Use in Metastatic Colorectal Cancer
por: Rodriguez, Mabel
Publicado: (2013) -
Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012) -
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
por: Giordano, Guido, et al.
Publicado: (2014)